Coronary Aneurysm Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 13, 2026 · Data accessed through Patsnap Life Sciences MCP servers.

This Coronary Aneurysm Indication Strategy Report ranks the opportunity using disease burden, biological rationale, unmet need, competitive intensity and transaction signals. It is designed for biopharma portfolio, search-and-evaluation, licensing and translational teams. The analysis focuses exclusively on Coronary Aneurysm; adjacent diseases are mentioned only when needed to interpret evidence or trial design.

Executive assessment

Coronary Aneurysm receives an overall strategic score of 69/100. The opportunity combines an unmet-need score of 85/100, competition score of 65/100 and market-attractiveness score of 76/100. Scores are directional decision aids, not forecasts: they synthesize the MCP evidence returned on the access date and explicitly penalize crowded development landscapes.

Disease background and strategic definition

Abnormal balloon- or sac-like dilatation in the wall of CORONARY VESSELS. Most coronary aneurysms are due to CORONARY ATHEROSCLEROSIS, and the rest are due to inflammatory diseases, such as KAWASAKI DISEASE.

For indication strategy, the disease label is only the starting point. A credible target product profile should specify the treatable population, diagnostic pathway, severity threshold, prior-therapy requirements, measurable clinical outcomes and treatment setting. In Coronary Aneurysm, value creation will depend on selecting a phenotype that is biologically coherent and commercially reachable, while avoiding a trial population so narrow that recruitment and launch become impractical.

The disease record is identified by Patsnap disease ID a242e9564fd944e3a718b3b0fc5e7bc3 and MeSH identifier D003323. These identifiers help keep searches reproducible when synonyms or spelling variants change.

Epidemiology and disease-burden evidence

Evidence signal 1: Prevalence and incidence of primary autoimmune hemolytic anemia and cold agglutinin disease in the United States, 2016–2023

Arizona; CA, California; CO, Colorado; CT, Connecticut; DC, District of Columbia; DE, Delaware; FL, Florida; GA, Georgia; HI, Hawaii; IA, Iowa; ID, Idaho; IL, Illinois; IN, Indiana; KS, Kansas; KY, Kentucky; LA, Louisiana; MA, Massachusetts; MD, Maryland; ME, Maine; MI, Michigan; MN, Minne­ sota; MO, Missouri; MS, Mississippi; MT, Montana; NC, North Carolina; ND, North Dakota; NE, Nebraska; NH, New Hampshire; NJ, New Jersey; NM, New Mexico; NV, Nevada; NY, New York; OH, Ohio; OK, Oklahoma; OR, Oregon; PA, Pennsylvania; RI, Rhode Island; SC, South Carolina; SD, South Dakota; TN, Tennessee; TX, Texas; UT, Utah; VA, Virginia; VT, Vermont; WA, Washington; WI, Wisconsin; WV, West Virginia; WY, Wyoming. https://doi-org.libproxy1.nus.edu.sg/10.1371/journal.pone.0323843.g003 Similarly, studies conducted across North America and Nordic countries report the incidence of CAD as approximately 0.3 per 100,000 persons and the prevalence as 1.6 per 100,000 persons [34]. Our study’s findings, while slightly higher for the CAD prevalence, are generally consistent with these previously published estimates and update the existing epidemi­ ological estimates. Although the standardized estimates varied across the three databases, the incidence and prevalence were similar when stratified by age group. This suggests that standardization did not fully account for underlying differences in the composition and representativeness of the overall US population across the three databases.

Review the underlying epidemiology source

Evidence signal 2: Heart Disease and Stroke Statistics—2021 Update

Aortic Aneurysm and Acute Aortic Syndromes ICD-9 441; ICD-10 I71. Prevalence • Estimating the prevalence of TAA is challeng- ing because of the relatively few studies in which screening has been performed in the general population. — The prevalence of TAA >5 cm incidentally iden- tified by community-based screening chest CT was estimated to be between 0.16% and 0.34% from studies performed between 1995 and 2003 in Japan and Germany.89,90 • AAA is more common in males than females, and its prevalence increases with age.91–94 — AAA is ≈4 times more common in males than females on the basis of data from an ultra- sound-based screening study of 125 722 veter- ans 50 to 79 years of age conducted between 1992 and 1997.95 ▪ In males, the prevalence of AAAs 2.9 to 4.9 cm in diameter ranged from 1.3% to 12.5% in individuals 45 to 54 and 75 to 84 years of age, respectively. In females, the prevalence of AAAs 2.9 to 4.9 cm in diameter ranged from 0% in the youngest to 5.2% in the old- est age groups.96 ▪ Approximately 1% of males between 55 and 64 years of age have an AAA ≥4.0 cm, and every decade thereafter, the prevalence increases by 2% to 4%.97,98 Incidence • Thoracic aortic disease (aneurysm and dissec- tion) incidence rates range between 3 and 16 per 100 000 per year in adults according to data from Sweden and the United Kingdom obtained between 1987 and 2012.99,100 • In 2010, the estimated annual incidence rate of AAA per 100 000 individuals was 0.83 (95% CI, 0.61– 1.11) to 164.57 (95% CI, 152.20–178.78) in individ- uals 40 to 44 and 75 to 79 years of age, respectively, accordi

Review the underlying epidemiology source

Evidence signal 3: 2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

– Overall prevalence of aortic aneurysms in any location was 3.1%. It was more common in men (4.0%) than women (0.7%; P<0.001). The prevalence of TAAs (defined as ascend­ ing aorta diameter ≥45 mm or descending aorta diameter ≥35 mm) was 2.4%, with more men (77%) than women (23%; P<0.001). In addition, the prevalence of AAAs (defined as diameter ≥30 mm) was 1.6%, with more men (89%) than women (11%; P<0.001). Among 5662 patients who underwent chest CT imag­ ing for any reason in 2016, 121 (2.14%) were incidentally found to have an ascending aorta measuring at least 4.0 cm.89 Incidence • In a multicenter observational cohort study (between September 2022 and November 2022) of 27 UK EDs, 5548 patients presented with potential AAD symptoms, and only 0.3% of patients had confirmed diagnosis of AAD.90 • From the National Patient Registry of Sweden (1998–2017) of men (65–79 years of age), the incidence of intact AAA repair increased from 72.8 per 100 000 PY before screening to 84.0 per 100 000 PY after initiation of screening.91 • Among a multicenter retrospective cohort from 2007 to 2023, which included 166 800 male smokers, 650 444 male nonsmokers, and 154 185 female smokers, the rate of AAA screening showed distinct trends across groups, with male smokers having the highest rate.92 – For male smokers, the AAA screening rate rose by an average of 1.9% annually starting in 2012, reaching a peak of 21.2% in 2023. Among male nonsmokers, the screening rate increased by 0.23%/y since 2001, peaking at 3.1% in 2023. Female smokers saw a slower rise, with a 0.09% annual increase beginn

Review the underlying epidemiology source

Epidemiology must be translated into an addressable population rather than copied into a revenue model. The recommended funnel is total prevalent or incident population → diagnosed population → clinically eligible segment → treated population → realistically accessible population. Analysts should separate point prevalence from lifetime prevalence, distinguish incidence from diagnosis rates, and avoid combining incompatible geographies or age bands.

For Coronary Aneurysm, the highest-value next epidemiology work is to quantify diagnostic delay, severity distribution, current treatment penetration and the proportion managed in specialist centers. Those variables often move the commercial case more than a single headline prevalence statistic.

Unmet need and patient-value thesis

Unmet need in Coronary Aneurysm should be framed as a measurable gap: inadequate disease control, treatment-limiting toxicity, burdensome administration, irreversible progression, delayed diagnosis, weak durability or lack of options for a defined subgroup. A program is strategically attractive when its mechanism can plausibly change one of those outcomes and when the clinical endpoint is accepted by regulators, physicians and payers.

The strongest development thesis would connect mechanism to a pre-specified responder population, demonstrate a clinically interpretable benefit, and reduce a meaningful part of the care burden. A weak thesis would rely only on statistical significance, use an endpoint disconnected from daily function, or assume that rarity automatically supports premium pricing.

Target mechanism: hERG

Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel (PubMed:10219239, PubMed:10753933, PubMed:10790218, PubMed:10837251, PubMed:11997281, PubMed:12063277, PubMed:18559421, PubMed:22314138, PubMed:22359612, PubMed:26363003, PubMed:27916661, PubMed:9230439, PubMed:9351446, PubMed:9765245). Channel properties are modulated by cAMP and subunit assembly (PubMed:10837251). Characterized by unusual gating kinetics by producing relatively small outward currents during membrane depolarization and large inward currents during subsequent repolarization which reflect a rapid inactivation during depolarization and quick recovery from inactivation but slow deactivation (closing) during repolarization (PubMed:10219239, PubMed:10753933, PubMed:10790218, PubMed:10837251, PubMed:11997281, PubMed:12063277, PubMed:18559421, PubMed:22314138, PubMed:22359612, PubMed:26363003, PubMed:27916661, PubMed:9230439, PubMed:9351446, PubMed:9765245). Forms a stable complex with KCNE1 or KCNE2, and that this heteromultimerization regulates inward rectifier potassium channel activity (PubMed:10219239, PubMed:9230439). Has no inward rectifier potassium channel activity by itself, but modulates channel characteristics by forming heterotetramers with other isoforms which are retained intracellularly and undergo ubiquitin-dependent degradation. Has no inward rectifier potassium channel activity by itself, but modulates channel characteristics by forming heterotetramers with other isoforms which are retained intracellularly and undergo ubiquitin-dependent degradation.

The proposed mechanism anchor for this landscape is KCNH2. Target selection does not imply that every Coronary Aneurysm patient is target-dependent. The translational package should establish expression or pathway activity in the intended tissue, human genetic or biomarker support, pharmacodynamic tractability, a therapeutic window and evidence that target modulation changes disease-relevant biology.

Critical de-risking experiments include orthogonal target engagement assays, dose–response work in disease-relevant models, biomarker qualification, assessment of compensatory pathways and explicit off-target safety testing. Human evidence should be weighted above model-only evidence, and negative clinical results in related mechanisms should be treated as learning assets rather than ignored.

Clinical development and competitive landscape

The MCP search returned 76 matched registered studies overall. The most recent records sampled for this report are:

• ChiCTR2600128228 — Multi-center Collaborative Clinical Study on Z-score of Coronary Artery Diameter by Ultrasound in Normal Children; status: Recruiting; phase: Not Applicable; sponsor(s): Children's Hospital Affiliated to Suzhou University; enrollment: 32000.
• NCT07683585 — Comparative Effectiveness of Dual Antihypertensive Regimens in Patients After Percutaneous Coronary Intervention (EDAM); status: Recruiting; phase: Not Applicable; sponsor(s): National Medical Research Center for Therapy and Preventive Medicine; enrollment: 207.
• ChiCTR2600126610 — Prediction of Long-Term Coronary Artery Aneurysm Risk in Children with Kawasaki Disease; status: Not yet recruiting; phase: Not Applicable; sponsor(s): Huzhou Central Hospital; enrollment: 250.

Raw trial count is not the same as commercial competition. Each program should be normalized by phase, modality, mechanism, sponsor strength, recruitment status, geography and the exact patient segment. Observational or investigator-led studies may reveal endpoint conventions and recruitment networks without representing product competition; discontinued assets may still expose safety or efficacy risks.

A differentiated Coronary Aneurysm program should define its advantage against the standard of care and the likely future standard at launch, not merely today's comparator. Useful whitespace can come from earlier intervention, a biomarker-selected subgroup, superior durability, safer chronic use, simpler delivery or a combination strategy with a clear contribution from each component.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned for Coronary Aneurysm. This is decision-relevant negative evidence: the indication may be under-transacted, may trade through broader disease labels, or may require target- and asset-level deal searches. It should not be interpreted as proof of zero partnering activity.

Transaction evidence should be interpreted alongside asset quality. Headline values may include contingent milestones, broad platform rights, multiple indications or undisclosed options. A defensible comparable set therefore requires matching disease, target, modality, development phase, territory and deal structure. Where direct comparables are sparse, triangulation across target-level and therapeutic-area transactions is preferable to forcing an unrelated deal into the valuation.

Potential partners will expect a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical development plan, intellectual-property position, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Early outreach is most productive when the program has a clear upcoming catalyst and a credible explanation of why the asset can win specifically in Coronary Aneurysm.

Market attractiveness and access considerations

The market opportunity is shaped by more than patient count. Diagnosis infrastructure, concentration of prescribers, treatment duration, administration setting, payer controls, competing generics, monitoring requirements and geographic reimbursement all influence attainable value. For Coronary Aneurysm, a launch model should test conservative, base and upside scenarios rather than assume uniform diagnosis and treatment.

Pricing power will depend on magnitude and durability of benefit, evidence quality, alternatives and budget impact. Developers should begin payer research before pivotal design so that endpoints, comparators and follow-up duration support both regulatory approval and reimbursement. Evidence generation should include health-resource use, quality of life and treatment burden when those are central to the value proposition.

Risks, evidence gaps and decision gates

• Disease-definition risk: validate that the proposed population is consistently diagnosed and recruitable.
• Biology risk: demonstrate that KCNH2 is causal or therapeutically relevant in the intended subgroup.
• Translation risk: link target engagement to a biomarker and a clinically meaningful endpoint.
• Competition risk: refresh the landscape before each investment gate and include mechanisms likely to launch first.
• Commercial risk: test diagnosis, access, pricing and adoption assumptions with physicians and payers.
• Data risk: treat zero-result searches as prompts for synonym and roll-up analysis, not definitive absence.

The recommended decision gates are: confirm epidemiology and segmentation; validate target biology in human evidence; establish a differentiated target product profile; obtain early clinical proof of mechanism; and only then scale investment toward registrational development or partnering. Each gate should have pre-agreed stop criteria.

Strategic recommendation

Coronary Aneurysm merits continued evaluation with an evidence-led, milestone-based strategy. The current signal supports prioritizing a narrowly defined population where KCNH2 biology can be measured and where the clinical benefit would be meaningful relative to available care. The program should advance only if follow-up work confirms population size, mechanistic coherence, endpoint feasibility and a credible route to differentiation.

For business development, the near-term goal is not to maximize the number of outreach targets; it is to assemble a partner-ready thesis that explains the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scores in this report provide a common language for comparing the opportunity while preserving the underlying evidence and uncertainties.

Methodology and source note

This report was assembled on August 13, 2026 using Patsnap MCP tools in a reproducible sequence: disease profile retrieval, epidemiology semantic search, target profile retrieval, clinical-trial search and pharmaceutical-deal search. Results reflect the returned records and query scope on that date. Counts may change as databases update, and the analysis is not medical, regulatory or investment advice.

The ranking weights are 40% unmet need, 25% inverse competitive intensity and 35% market attractiveness. Qualitative judgments are informed by disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Readers should rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio decision.

Conclusion

Coronary Aneurysm offers a tractable strategic question: can a biologically grounded program deliver a material patient benefit in a clearly identifiable population and do so with sufficient differentiation to earn adoption? The evidence assembled here gives teams a starting map, while the identified gaps define the next diligence plan. Use the linked MCP marketplace to refresh the evidence as programs, trials and transactions evolve.